Robert Celt
New Member
If you are a chronic pain patient, you can be excused for saying, "Well, how about that!"
The U.S. Drug Enforcement Agency has granted approval for a nonprofit to study marijuana's medical benefits on military veterans suffering from combat-related psychological disorders.
The Multidisciplinary Association for Psychedelic Studies (MAPS), a California-based nonprofit that studies medical uses of psychotropic drugs, will conduct the clinical trial, which will be a double-blind, placebo-controlled trial using the whole plant (not an extract or pill version). The trial is the first in U.S. history to receive full approval from the DEA and FDA.
The study will examine whether medical marijuana can treat Post-Traumatic Stress Disorder in 76 U.S. military veterans. The veterans have treatment-resistant PTSD and haven't found relief from other medications. The study will look into how different strains and doses of marijuana can benefit the veterans and look into potential side effects, a press release from MAPS says.
Meantime, a U.S. Senate Committee has passed an amendment to protect state medical marijuana laws from federal interference.
"We should respect the rights of the states who are going through this process," Maryland Senator Barbara Mikulski said in a brief debate prior to the vote. "The DEA has enough to do keeping illegal drugs out of our country at the border, rather than interfering where a state has determined through an open process that it wants to do these sales."
The Mikulski amendment is expected to pass both in the full Senate as well as in the House of Representatives.
The amendment has been included previous funding bills, both of which were passed by Congress and signed by President Obama. The amendment is essentially identical to the Rohrabacher-Farr Amendment, named after its House sponsors Dana Rohrabacher (R-CA) and Sam Farr (D-CA). The amendment must be voted on each year to remain in effect, but has not had a vote in the House yet this year.
Since first being included in the 2015 budget, the amendment has already had some impact on the medical marijuana community. In October 2015, a federal judge in California ruled that the amendment prevents the DEA from bringing legal action against medical marijuana providers and others participating in the program if they are acting in compliance with state medical marijuana laws.
News Moderator: Robert Celt 420 MAGAZINE ®
Full Article: National Pain Report Medical Marijuana Update
Author: Staff
Contact: National Pain Report
Photo Credit: None found
Website: National Pain Report
The U.S. Drug Enforcement Agency has granted approval for a nonprofit to study marijuana's medical benefits on military veterans suffering from combat-related psychological disorders.
The Multidisciplinary Association for Psychedelic Studies (MAPS), a California-based nonprofit that studies medical uses of psychotropic drugs, will conduct the clinical trial, which will be a double-blind, placebo-controlled trial using the whole plant (not an extract or pill version). The trial is the first in U.S. history to receive full approval from the DEA and FDA.
The study will examine whether medical marijuana can treat Post-Traumatic Stress Disorder in 76 U.S. military veterans. The veterans have treatment-resistant PTSD and haven't found relief from other medications. The study will look into how different strains and doses of marijuana can benefit the veterans and look into potential side effects, a press release from MAPS says.
Meantime, a U.S. Senate Committee has passed an amendment to protect state medical marijuana laws from federal interference.
"We should respect the rights of the states who are going through this process," Maryland Senator Barbara Mikulski said in a brief debate prior to the vote. "The DEA has enough to do keeping illegal drugs out of our country at the border, rather than interfering where a state has determined through an open process that it wants to do these sales."
The Mikulski amendment is expected to pass both in the full Senate as well as in the House of Representatives.
The amendment has been included previous funding bills, both of which were passed by Congress and signed by President Obama. The amendment is essentially identical to the Rohrabacher-Farr Amendment, named after its House sponsors Dana Rohrabacher (R-CA) and Sam Farr (D-CA). The amendment must be voted on each year to remain in effect, but has not had a vote in the House yet this year.
Since first being included in the 2015 budget, the amendment has already had some impact on the medical marijuana community. In October 2015, a federal judge in California ruled that the amendment prevents the DEA from bringing legal action against medical marijuana providers and others participating in the program if they are acting in compliance with state medical marijuana laws.
News Moderator: Robert Celt 420 MAGAZINE ®
Full Article: National Pain Report Medical Marijuana Update
Author: Staff
Contact: National Pain Report
Photo Credit: None found
Website: National Pain Report
